Arthneeti
SL

Suven Life Sciences Ltd

Q2 FY27Healthcare Services

Suven Life Sciences Q2 Results 2026 (FY27) statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and capex.

Revenue
₹1Cr
Net profit
−₹107Cr
Margin
−9243.3%

Suven Life Sciences Ltd Q2 FY27 key numbers

Revenue
Revenue from operations for the quarter ended September 30, 2026, is Rs. 119.86 lakhs (Consolidated and Standalone).

As stated in Suven Life Sciences Ltd's Q2 FY27 results statement · published 6 Nov 2026. Reported figures, not investment advice.

Based on Suven Life Sciences Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

Price₹265
Market cap₹7.5K Cr

The short version

Revenue from operations for the quarter ended September 30, 2026, is Rs. 119.86 lakhs (Consolidated and Standalone). Quarterly EBITDA: Rs.

From Suven Life Sciences Ltd's Q2 FY27 earnings-call transcript · updated 6 Nov 2026.

How did Suven Life Sciences' revenue grow in the September 2026 quarter?

  • Revenue from operations for the quarter ended September 30, 2026, is Rs. 119.86 lakhs (Consolidated and Standalone).
  • Year-on-year comparison: Rs. 91.92 lakhs for the quarter ended September 30, 2025, indicating a revenue increase of approximately 30.3%.
  • Total income (including other income) for the quarter is Rs. 793.30 lakhs compared to Rs. 469.72 lakhs in the same quarter last year.

What happened to Suven Life Sciences' margins in Q2 FY27?

See what Suven Life Sciences Ltd said on profitability & margins — free account, 30 seconds.

What capex is Suven Life Sciences planning?

See what Suven Life Sciences Ltd said on capital expenditure plans — free account, 30 seconds.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
1Health X Platform
Rev 1Mar 1
2Chandan Healthca
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Suven Life Sciences raising money or cutting debt?

See what Suven Life Sciences Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Suven Life Sciences' order book?

The investor presentation states the following regarding order book, order inflow, or pending orders: - The financial results and disclosures focus on unaudited standalone and consolidated financials, audit review reports, assets & liabilities, and cash flow statements. - The report centers on financial performance, subsidiary interim results, equity issues, employee stock options, and balances as of September 30, 2026.

Suven Life Sciences Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Suven Life Sciences Ltd Q2 FY27 results — key figures

Suven Life Sciences Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue1
Operating profit (EBITDA)-111
Operating margin-9243.3%
Profit before tax-107
Net profit (PAT)-107
EPS (₹)-3.77

Source: Suven Life Sciences Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1 Cr, net loss ₹107 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Suven Life Sciences's management said in earlier quarters

Earlier calls (6)

Others in Healthcare Services this season

  • Nidan Laboratories & Healthcare (Q2 FY27)

    Operating Margin: Not explicitly stated as a percentage; however, total income from operations is Rs 1,201.76 lakhs, so approximate operating margin = (EBITDA…

  • Aster DM Quality (Q2 FY27)

    Q2 FY27 revenue: INR 2,829 Cr, up 19% YoY from INR 2,382 Cr in Q2 FY26 (Page 6, 9, 10). Key investor presentation takeaways from Aster DM Quality Care Ltd's Q2

  • Fortis Healthcare (Q2 FY27)

    Q2FY27 consolidated revenue: INR 2,735 Cr, up 17.3% YoY (Q2FY26: INR 2,331 Cr) [Pages 11, 33] . Key investor presentation takeaways from Fortis Healthcare Ltd's

  • Dr Agarwal's Hea (Q2 FY27)

    Q2 FY27 revenue from operations: ₹655 Cr, up 31.4% YoY from ₹499 Cr in Q2 FY26 (Page 24) . Key investor presentation takeaways from Dr Agarwals Health Care Ltd'

Compare:vs Apollo Hospitalsvs Max Healthcarevs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Suven Life Sciences Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Suven Life Sciences Ltd Q2 FY27 results?

Revenue from operations for the quarter ended September 30, 2026, is Rs. 119.86 lakhs (Consolidated and Standalone). Quarterly EBITDA: Rs.

What is Suven Life Sciences Ltd share price analysis?

Suven Life Sciences Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹7,484 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Suven Life Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.